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The effect of haloperidol administration  lipid peroxidation and glutathione/protein thioi homeostasis in the brain was examined 4 h following 
subcutaneous administration f a single dose of haloperidol; 1.0, 1.5, 2.0 or 2.5 mg/kg b.wt. Giutathione (GSH) levels decreased significantly in
cortex, striatum and midbrain after haloperidol administration. Maximal decrease of GSH was observed in the :~triatum. The depleted GSH was 
recoverable as protein glutathione mixed disulfide (Pr-SSG) with concomitant loss of protein thiols (Pr-SH) in all the regions of the brain 
examined. Administration of !,5 mg/kg b.wt. of haloperidol resulted in significant depletion of GSH in striatum and midbrain as compared to 
that after administration f the lower dose of !.0 mg/kg b.wt. of haloperidol. However, administration f higher doses of haloperidol (2.0 and 2.5 
mg/kg b.wt.) did not result in greater depletion of GSH; the GSH levels were not significantly different from that observed following the 
administration f 1.5 mg/kg b.wt. of haloperidol. However, Pr-SSG levels increased ose-dependently following haloperidol administration. The 
total GSH recovered as sum of GSH and Pr-SSG was significantly higher than controls in striatum and midbrain following administration of
higher doses of haloperidol, namely, 2.0 and 2.5 mg/kg b.wt. The depleted GSH was not recoverable as glutathione disulfide (GSSG). GSSG 
levels were not significantly different from controls 4 h after administration f 1.5 mg/kg b.wt. of haloperidol. The levels of malondialdehyde 
(indicative of lipid peroxidation) increased significantly as compared to control evels (280-220%) following administration f i.0 and 1.5 mg/kg 
b.wt. of halopclidol. Thereafter, the malondialdehyde levels in brain regions decreased and were only (186-150%) of control levels after 
administration of 2.() and 2.5 mg/kg b.wt. of haloperidol, respectively. The present study demonstrates that administration of low doses of 
haloperidol results in depletion of GSH and increased levels of malondialdehyde. However, administration f higher doses of haloperidol results 
in anenualion of peroxitlative damage with concomitant increase in the total GSH recovered as sum of free GSH and GSH bound to protein 
thiols (Pr-SSG). 
INTRODUCTION 
Haloperidol, an antipsychotic drug, is commonly 
used for the treatment of schizophrenia 2. Haloperidol 
has high affinity for the dopamine receptor (D 2 recep- 
tor) and administration f haloperidol results in block- 
ade of D 2 receptor 2,~.a0. Administration of neuroleptics 
like haloperidol also results in the increased turnover 
of dopamine leading to increased production of hydro- 
gen peroxide (H20 2) following metabolism of 
dopamine by monoamine oxidase -~.4.t2. One of the ma- 
jor side effects of neuroleptic therapy is the develop- 
ment of extrapyramidal symptoms following adminis- 
tration of the drug ~7. These extrapyramidal symptoms 
are alleviated following the administration of higher 
doses of haloperidol t°'ll.18. The biochemical mecha- 
nisms underlying the pathophysiology of these side 
effects has been a subject of intense study and various 
hypotheses have been put forth 7''~'24. Recent studies 
have focussed on the possible role of reactive oxygen 
s oecies in the pathogenesis of extrapyramidal effects 8. 
The generation of reactive oxygen species due to in- 
creased turnover of dopamine is a source of oxidative 
stress 5. 
Glutathione (GSH), the major non-protein thiol in 
the cell, acts as an antioxidant and helps to maintain 
the protein-thiol homeostasis in the cell t'~. Glutathione 
peroxidase plays an important role in the detoxification 
of hydrogen peroxide with the concomitant oxidation 
of GSH to its oxidized form GSSG. Oxidized glu- 
tathione which is normally present in the cells in very 
low amounts is reduced back to GSH by glutathione 
reductase utilizing reducing equivalents of NADPH t6. 
If the production of GSSG overwhelms the NADPH 
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supply in the cell, the GSSG/GSH homeostasis i
disturbed. Thus, increase in GSSG is often an indica- 
tion of oxidative stress. 
Administration of haloperidol (1.0 mg/kg b.wt.) to 
mice has been shown to result in increased levels of 
GSSG in striatum, 1h after dosage. This increase was 
alleviated by the administration f monoamine oxidase 
inhibitor deprenyl, indicating that the oxidative stress 
was probably generated following haloperidol adminis- 
tration, which could be prevented by inhibition of 
dopamine turnover 5.
The present study was carried out to determine the 
GSH-protein thiol homeostasis following administra- 
tion of varying doses of haloperidol. The formation of 
reactive oxygen species was also measured using the 
fluorescent probe (2',7'-dichlorofluorescin diacetate) t4 
and the levels of malondialdehyde (MDA) were deter- 
mined as an estimate of lipid peroxidation products. 
MATERIALS AND METHODS 
Materials 
Reduced glutathione (GSH), oxidized glutathione (GSSG), 
NADPH, glutathione reductase, o-phthaldialdehyde, ithiothreitol, 
iodoacetic acid and 5.5, dithio bis-(2-nitrobenzoic a id) were ob- 
tained from Sigma Chemical Co., St. Louis, MO, USA. 2',7'-Dichlo- 
rofluorescin diacetate (DCFH-DA) and 2',7'-dichlorofluorescein 
(DCF) were obtained from Molecular Probes Inc. (Eugene, OR, 
USA). Haloperidol (injectable ampoules; 5 mg/ml) was obtained 
from Searle India Ltd., Bombay, India. All other reagents were of 
analytical grade. 
An#rials 
The experiments were performed on Sprague-Dawley rats weigh- 
ing 200-250 g and aged 3-4 months, obtained from the Central 
Animal Research Facility of the Institute. Animals had free access to 
pelletted diet (Lipton India Ltd., Calcutta, India) and water ad 
libitum. Haloperidol was diluted in saline and administered subcuta- 
neously to groups of rats at doses of 1.0, i.5, 2.0 and 2.5 mg/kg b.wt., 
respectively. Control animals, which received vehicle alone were 
incorporated in each experiment. After 4 h, the animals were an:es- 
thetized with ether and perfused transcardially with ice-cold normal 
saline (20 ml) to remove blood from the brain tissue. The rats were 
decapitated, brains were rapidly removed, and the following regions 
were dissected out: cortex (CT), striatum (ST) and midbrain (MB). 
The tissues were frozen immediately in liquid nitrogen. 
Assay of GSH and GSSG 
Brain regions (CT, ST and MB) from one half of the cerebral 
hemisphere were weighed in frozen condition and homogenized in 2 
vols. of perchloric acid (10% v/v containing 1.0 mM EDTA). The 
homogenate was centrifuged at 8,000x g for 2 rain. One aliquot of 
the supernatant was used for the assay of total GSH by enzymatic 
recycling method 31. An aliquot of the acid supernatant (0.1 ml) was 
transferred to an Eppendorf tube containing solid sodium bicarbon- 
ate ( ~ 50 mg). Immediately 10 p.I of iodoacetic acid (0.2 M in water) 
was added. The tube was kept in dark at room temperature for 1 h. 
Later the contents of the tubes were centrifuged and an aliquot was 
used for analysis of GSSG by enzymatic recycling method zs. GSSG 
levels were also measured following derivatization of GSH with 
N-ethylmaleimide as described 26. 
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Assay of protein glutathione mixed isulfides 
The levels of protein glutathione mixed disulfide (Pr-SSG) in the 
acid precipitated pellet was measured as described TM. The pellet 
was washed twice in ethanol (1.0 mi) and sonicatcd for 4 rain. The 
pellets were resuspended in 4-morpholinepropanesulfonic acid buffer 
(MOPS, 50 raM, pH 8.0) containing dithiothreitol (25 mM). The 
mixture was sonicated for .5 rain and incubated for 1 h at 37°C. Later 
the samples were deproteinized with perchloric acid (70% v/v), 
mixed and frozen in liquid nitrogen, thawed and centrifuged. An 
aliquot of the supernatant was treated with o-phthaldialdehyde and 
the reaction mixture was kept in dark at room temperature for 10 
rain. The fluorescence was recorded following excitation at 350 nm 
and emission at wavelength 420 nm in an Aminco Bowman spec- 
trophotofluorometer. The amount of GSH equivalents present as 
Pr-SSG was quantified from a standard curve of GSH. 
Assay of protein thiols 
The brain regions from the other half of the cerebral hemisphere 
were homogenized in 9 vols. of potassium phosphate buffer (0.1 M, 
pH 7.4). An aliquot of the homogenate was treated with an equal 
volume of perchloric acid (5% v/v).~ centrifuged and the concentra- 
tion of protein thiol was estimated~in the acid precipitated pellet as 
described earlier ~. 
Aliquots of the remaining homogenate were used for the assay of 
malondialdehyde, measured as thiobarbiluric acid reacive pro&lets 2°. 
An aliquot of the homogenate was incubated with 2',7'-dichloro- 
fluorescin diacetate (5 #M in methanol) for 15 min at 37°C for the 
estimation of reactive oxygen species. The reaction was termilmted 
by chilling the reaction mixture in ice. The formation of fluorescent 
oxidized derivative, namely, 2',7'-dichiorofluorescein wasmonitored 
using an excitation wavelength of488 nm and emission wavelength of
525 nm in an Aminco Bowman spectrophotofluorometer. The equiv- 
alent levels of oxygen radicals was quantified from a DCF standard 
curve 14. 
Data were analysed using one-way analysis of variance (ANOVA) 
and Duncan's test. Values are represented asmean + S.D. 
RESULTS 
Following administration of a single dose of 
haloperidol (1.0 and 1.5 mg/kg b.wt.), GSH levels in 
cortex were 85 and 83% of control levels (Fig. 1A). 
Administration of a higher dose (2.0 mg/kg b.wt.) did 
not result in further GSH loss and the GSH levels were 
84% of controls. Substantial amount of the depleted 
GSH was recoverable as Pr-SSG. Pr-SSG levels in- 
creased dose-dependently in the cortex as shown in 
Fig. lB. The amount of GSH gained as Pr-SSG follow- 
ing lower doses of haloperidol (1.0 and 1.5 mg/kg 
b.wt.) was 0.33 and 0.37/.tmol of GSH equivalent/g 
tissue over the control levels. An increase in the dose 
(2.0 mg/kg b.wt.) resulted in an increase in the amount 
of Pr-SSG formed and 0.45 ~mol of GSH equivalents/g 
tissue was recovered as Pr-SSG. The formation of 
Pr-SSG was accompanied by the loss of protein thiois 
(Pr-SH). The Pr-SH lost in cortex (Fig. 1C) following 
1.0 and 1.5 mg/kg b.wt. of haloperidol wa~ 1.17 and 
1.37/~mol of thiol equivalent/g tissue. An increase in 
the dose (2.0 mg/kg b.wt.) resulted in lesser loss of 
protein thiols (1.13/~mol f thiol equivaleat/g tissue). 
Further increase in the dose (2.5 mg/kg b.wt.) resulted 
in lower loss of protein thiols (0.78 /~mol of thiol 
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equivalent/g tissue). The total GSFI recovered (GSH 
+ Pr-SSG) was not significantly different from un- 
treated controls following administration of 1.0 and 1.5 
mg/kg b.wt. of haloperidol in the cortex (Fig. 1D). The 
total GSH levels recovered in the cortex were 108 and 
106% of control levels after administration of 2.0 and 
2.5 mg/kg  b.wt. of halopefidol, respectively. 
Following subcutaneous administration of a single 
dose of haloperidol (1.0 and 1.5 mg/ke  b.wt.), GSH 
levels in the striatum were 76 and 74% of controls (Fig. 
2A). On increasing the dose (2.0 and 2.5 mg/kg b.wt.), 
the GSH levels were 74 and 78% of control levels. The 
depleted GSH wa,; recoverable as Pr-SSG as shown in 
Fig. 2i3. "~'he Pr-SSG levels increased in a dose-depen- 
dent magmer following administration of increasing 
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(1.0, 1.5, 2.0 and 2.5 mg/kg b.wt.) subcutaneously. Animals were 
sacrificed 4 h following the dosage. Values are expressed as/zmol of 
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animals were used). Asterisks indicate values significantly different 
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Fig. 2. The effect of haloperidol administration striatal concentra- 
tions of (A) GSH, (B) Pr-SSG, (C) Pr-SH and (D) total GSH 
(GSH+PrSSG) following administration of increasing doses of 
haloperidol. Rats were administered varying doses of haloperidol 
(1.0, 1.5, 2.0 and 2.5 mg/kg b.wt.) subcutaneously. Animals were 
sacrificed 4 h later following the dosage. Values are expressed as 
/~mol of GSH equivalent/g tissue (raM) and are mean + S.D. (n --- 4- 
11, except for the dose of 1.0 mg/kg b.wt. of haloperidol wherein 3
animals were used). Asterisks indicate values ignificantly different 
from controls (P < 0.05). 
doses of haloperidol (1.0, 1.5~ 2.0 and 2.5 mg/kg  b.wt.). 
The levels were 0.37 and 0.65 /~mol of GSH equiva- 
lent/g tissue as compared to control levels of 0.07 
/zmoi of GSH equivalent/g tissue. The amount of 
protein thio!s lost in the striatum was also dose-depen- 
dent following administration of 1.0 and 1.5 mg/kg  
b.wt. of haloperidoi as shown in Fig. 2C. The concen- 
tration of protein thiois were 68 and 57% of control 
levels. In contrast, after administration of higher doses 
of haloperidoi (2.0 and 2.5 mg/kg  b.wt.) the levels of 
protein thiols were 64 and 73% of corresponding con- 
trols indicating a recovery of protein thiol status. Fur- 
ther, the total GSH recovered as sum of GSH and 
Pr-SSG was not significantly different from untreated 
controls following administration of 1.0 and 1.5 mg/kg  
b.wt. of haioperidol in the striatum (Fig. 2D). However, 
the concentrations of total GSH recovered was signifi- 
cantly higher (112 and 117% of control) in the striatum 
following administration f higher doses of haloperidol 
(2.0 and 2.5 mg/kg bowt.). 
The levels of MDA in the cortex (indicative of lipid 
peroxidation) increased significantly as compared to 
untreated controls (228-220%) following administra- 
tion of 1.0 and 1.5 mg/kg b.wt. of haloperidol (Fig. 
3A). After administration f 2.0 and 2.5 mg/kg b.wt. of 
haloperidol they were 186-170% of controls. The reac- 
tive oxygen species were measured using the fluores- 
cent probe 2',7'-diehlorofluorescin diacetate. The lev- 
els of oxy-free radicals measured as 2',7'-dichlorofluo- 
rescein were 153 and 202% after 1.0 and 1.5 mg/kg 
b.wt. of haloperidol. However, the levels of 2',7'-di- 
chlorofluorescein decreased significantly and were 126 
and 109% of controls after administration of 2.0 and 
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Fig. 3. The effect of haloperidol administration cortical (CT) and 
striatal (ST) concentrations of MDA, (A and A') and formation of 
reactive oxygen species (B and B'), following administration of
varying doses of haloperidol. Rats were administered varying doses 
of haloperidol (1.0, 1.5, 2.0 and 2.5 mg/kg b.wt.) subcutaneously. 
Animals were sacrificed 4 h later following the dosage. Values are 
expressed as nmoi/g tissue and are mean + S.D. (n = 4-8, except for 
the dose of 1.0 mg/kg b.wt. of haloperidol wherein 3 animals were 
used). Asterisks indicate values ignificantly different from untreated 
controls (P < 0.05). 
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Asterisks indicate values significantly different from corresponding 
controls (P < 0.05). 
2.5 mg/kg b.wt. of haloperidol (Fig. 3B). The levels of 
MDA in the striatum were 223 and 221% of controls, 
following administration f 1.0 and 1.5 mg/kg b.wt. of 
haloperidol (Fig. 3A'). Following an increase in the 
dose (2.0 and 2.5 mg/kg b.wt.) the MDA levels de- 
creased and were 170 and 149% of untreated controls. 
The generation of reactive oxygen species measured as 
the formation of the fluorescent 2',7'-dichlorofluo- 
rescein increased with increasing doses of haloperidol 
up to 1.5 mg/kg b.wt. (150-225%). Further increase in 
the dose of haloperidol (2.0 and 2.5 mg/kg b.wt.) 
resulted in decreased production of reactive oxygen 
species (Fig. 3B') and the levels were not significantly 
different from control. 
In the midbrain of animals treated with haloperidol 
(Fig. 4A), maximal depletion of GSH was observed 
following a dose of 1.5 mg/kg b.wt. of haloperidol. The 
GSH levels observed were 83% of untreated controls. 
However, the levels of GSH did not decrease further 
following higher doses of haloperidol (2.0 and 2.5 
mg/kg b.wt.) and were 88% and 83% of corresponding 
controls. The loss of GSH was accompanied by an 
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TABLE I 
Ghaathione disulfide (GSSG) concentration i  rat striamm following 
treatment with haloperidol 
Sprague-Dawley rats were administered a single dose of haloperidol 
(!.5 mg/kg b.wt.) subcutaneously. Animals were sacrificed after (A) 
I h or (B) 4 h and GSSG concentration i striatum was measured as 
described "-~. Values were mean _+ S.D. (n = 5). 
Expt. Control GSSG (~tmoi / g tissue) Percent 
haloperidol bwrcase 
A 0.017 + 0.002 0.035 + 0.003 * 206% 
B 0.016+(}.004 0.018+0.002 n.s. 
* Indicates values significantly different from conrols (P  < 0.05) and 
n.s. indicates values not significantly different from controls. 
increase in the formation of Pr-SSG as shown in Fig. 
4B, The Pr-SSG levels increased in a dose-dependent 
manner in the midbrain. The levels of Pr-SSG were 
0.18 and 0.29/zmol of GSH equivalent/g tissue follow- 
ing doses of 1.0 and 1.5 mg/kg b.wt. of haloperidol. 
Increasing the dose (2.0 and 2.5 mg/kg b.wt.) led to 
increase in Pr-SSG levels (0.41 and 0.44 #tool of GSH 
equivalent/g tissue. The total GSH recovered as sum 
of GSH and Pr-SSG was compared with corresponding 
controls. The total GSH recovered was not significantly 
different from controls following administration of 1.0 
and 1.5 mg/kg b.wt. of haloperidol. However, the total 
GSH recovered was higher than the controls in the 
midbrain (Fig. 4C) following administration of higher 
doses of haloperidol namely, 2.0 and 2.5 mg/kg b.wt. 
(116 and 114%, respectively). 
Although GSH content decreased the GSSG levels 
did not increase significantly 4 h after haloperidol 
dosage as indicated in Table I. The GSSt3 concentra. 
tion, however, increased in the striatum, 1 h after 
administration of haloperidoi (1.5 mg/kg b.wt.) and 
was 206% of control as shown in Table i. The depleted 
GSH, recovered as GSSG, was 7% of the GSH lost at 
this time point. The GSH level in striatum 1 h after 
administration of 1.5 mg/kg b.wt. of haloperidol was 
1.11 ~mol of GSH/g tissue (data not shown) which 
indicated the depletion of 31% of the GSH levels 
present in untreated rat brain striatum. 
DISCUSSION 
Administration of increasing doses (1.0, 1.5, 2.0 and 
2.5 mg/kg b.wt.)of haloperidol did not result in dose 
dependent decrease of GSH in striatum, cortex and 
midbrain. Maximal depletion (26%) was noted in the 
striatum following administration f 1.5 mg/kg b.wt. of 
haloperidol. The GSH lost was not recoverable as 
GSSG. The GSSG levels were not significantly differ- 
ent from untreated controls, 4 h after administration f 
haloperidol (1.5 mg/kg b.wt.), although, GSSG levels 
were significantly increased (206%), 1 h following ad- 
ministration of haloperidol (1.5 mg/kg b.wt.). This is in 
concurrence with earlier report wherein GSSG levels 
were observed to be significantly higher following 
haloperidol administr:~tion to mice 5. The GSSG in- 
crease was transient and was not observed 4 h after 
dosage although at this time enhanced oxidative stress 
was apparent as determined by increased MDA and 
Pr-SSG levels. The absence of elevation of GSSG 
levels may not always reflect lack of oxidative stress as 
demonstrated in the present study. It is therefore nec- 
essary to examine GSH and Pr-SSG levels in addition 
to determining GSSG concentration. 
The depleted GSH was essentially recovered as Pr- 
SSG in all the regions of brain that were examined. 
This is similar to. the observation made with brain 
mitochondria subjected to oxidative stress by treatment 
with t-butyl hydroperoxide 23.The depleted GSH was 
recovered essentially as Pr-SSG and less than 5% of 
the depleted GSH was recovered as GSSG in the 
mitochondria. During severe hepatic oxidative stress 
when the NADPH levels are not sufficient o reduce 
all of the GSSG formed to GSH (through glutathione 
reductase), the GSSG is effiuxed out of the cell, thus 
preventing the formation of excessive Pr-SSG and Pr- 
SS-Pr which can lead to membrane damage. Thus, in 
hepatocytes subjected to oxidative stress, the formation 
of Pr-SSG accounts for only 15% of the GSH depleted 
in liver 6. In the brain, even under less severe oxidative 
stress, Pr-SSG formation accounts for over 90% of the 
depleted GSH. The formation of protein mixed disul- 
fides may have far reaching consequences by affecting 
neuronal functions. 
The Pr-SSG levels increased linearly with increasing 
doses of haloperidol in both striatum and midbrain. 
The total GSH recovered as GSH and Pr-SSG was 
calculated and compared with corresponding controls. 
The amount of total striatai GSH recovered (GSH + 
Pr-SSG) was not significantly different from controls 
following administration f 1.0 and 1.5 mg/kg b.wt. of 
haloperidol, but increased significantly (112 and 117% 
of control) after a dose of 2,0 and 2,5 mg/kg b,wt. of 
haloperidol. This indicates that a threshold level exists 
in the brain and depletion of GSH beyond that level 
results in increased recovery of GSH, probably due to 
increased synthesis of GSH. Similar threshold levels 
are also observed in liver, wherein depletion of about 
80% hepatic GSH results in rebound of GSH due to 
increased synthesis ~3,22. However, in the brain in- 
creased recovery is observed following depletion of 
about 25% of the GSH present in brain. The highest 
recovery of GSH was observed in striatum and mid- 
brain (sites of haloperidol action), while the recovery in 
the cortex was only 108% of corresponding levels of 
GSH in control. 
The formation of Pr-SSG was accompanied by loss 
of protein thiols (Pr-SH). The amount of Pr-SH lost in 
striatum was significantly higher than the amount of 
Pr-SSG formed indicating the formation of protein 
mixed disulfide (Pr-SS-Pr). Concurrent with the in- 
creased recovery of GSH, the amount of Pr-SH lost 
also decreased. 
A similar trend was observed in the levels of malon- 
dialdehyde. The MDA levels in striatum were 223 to 
221% of control after 1.0 and 1.5 mg/kg b.wt. of 
haloperidol and mey decreased substantially (150% of 
control) after administration of 2.5 mg/kg b.wt° of 
haloperidol. The measurement of reactive oxygen 
species al~o revea~.ed an i~crease in the fluorescent 
derivatives with increasing doses of haioperidol up to 
1.5 mg/kg b.wt. and thereafter they decreased and 
were not significantly different from the controls fol- 
lowing administration of 2.0 and 2.5 mg/kg b.wt. of 
haloperidol. While the use of 2',7'-dichlorofluorescin 
diacetate gives a measure of reactive oxygen species, 
MDA measures the product of lipid peroxidation and 
this may be the reason that reactive oxygen species as 
measured by 2',7'-dichlorofluorescin diacetate were 
similar to controls after 2.0 and 2.5 mg/kg b.wt. of 
haloperidol, while MDA levels showed a more gradual 
decrease. 
The present study demonstrates that administration 
of haloperidol results in production of oxidative stress 
as demonstrated by decreased GSH levels and in- 
creased Pr-SSG level and MDA levels, and reactive 
oxygen species generation. However, administration of 
higher doses of haloperidol results in increased recov- 
ery of GSH with concomitant decrease in oxidative 
stress. An inverse relationship is known to exist be- 
tween the dose of haloperidol administered and the 
observation of extrapyrmidal symptoms. Thus, higher 
doses of haloperidol result in lower incidence of ex- 
trapyrimidal symptoms 2s. Whether this clinical phe- 
nomenon observed in human population is related to 
the changes in GSH homeostasis remains to be estab- 
lished. Nevertheless the present study clearly demon- 
strates that haloperidol administration generates oxida- 
tive stress. Hence, co-administration of antioxidants 
like vitamin E may help in overcoming this oxidative 
stress is. 
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